APP下载

光子嫩肤技术联合复方黄柏液治疗面部激素依赖性皮炎患者的效果

2018-08-30苏春志黎超伟曾洲平

中国医药导报 2018年14期

苏春志 黎超伟 曾洲平

[摘要] 目的 探討光子嫩肤技术联合复方黄柏液治疗面部激素依赖性皮炎(FCAD)患者的效果。 方法 选取2015年6月~2017年5月广东省高州市人民医院皮肤科确诊的FCAD患者96例,按照随机数字表法分为三组,每组各32例。黄柏组外用他克莫司软膏+复方黄柏液湿敷,光子组外用他克莫司软膏+光子嫩肤仪,联合组外用他克莫司软膏+复方黄柏液湿敷+光子嫩肤技术,疗程均为8周。比较三组患者治疗后皮肤屏障功能指标[经皮水分丢失(TEWL)值、表皮含水量、表皮油脂含量]、治疗前后皮肤病生活质量指标(DLQI)得分以及疗效,记录并比较三组患者治疗期间不良反应情况及疗程结束后8周内复发情况。 结果 治疗后三组患者皮肤屏障功能指标、DLQI得分以及总有效率比较差异均有统计学意义(P < 0.05)。治疗后联合组TEWL值低于光子组和黄柏组,光子组低于黄柏组,差异均有统计学意义(P < 0.05);治疗后联合组表皮含水量、表皮油脂含量、总有效率均高于光子组和黄柏组,光子组高于黄柏组,而联合组DLQI得分低于光子组和黄柏组,光子组低于黄柏组,差异均有统计学意义(P < 0.05)。治疗期间三组不良反应发生率比较差异无统计学意义(P > 0.05),且疗程结束后8周内均无复发情况。 结论 光子嫩肤技术联合复方黄柏液及他克莫司软膏治疗FCAD效果显著,并且可显著改善患者皮肤屏障功能,提高患者生活质量,安全性高,值得临床推广。

[关键词] 光子嫩肤技术;复方黄柏液;面部激素依赖性皮炎

[中图分类号] R657.42 [文献标识码] A [文章编号] 1673-7210(2018)05(b)-0107-05

Effect of photon rejuvenation technology combined with Compound Cortex Phellodendri Liquid in the treatment of patients with facial corticosteroid addictive dermatitis

SU Chunzhi LI Chaowei ZENG Zhouping

Department of Dermatology, Gaozhou People's Hospital, Guangdong Province, Gaozhou 525200, China

[Abstract] Objective To explore the effect of photon rejuvenation technology combined with Compound Cortex Phellodendri Liquid in the treatment of patients with facial corticosteroid addictive dermatitis (FCAD). Methods Ninety-six cases of patients diagnosed as FCAD in Department of Dermatology, Gaozhou People's Hospital from June 2015 to May 2017 were randomly divided into 3 groups, with 32 patients in each group. The Cortex Phellodendri group was treated with Compound Cortex Phellodendri Liquid combined with Tacrolimus Ointment. The photon group was treated with Tacrolimus Ointment combined with photon rejuvenation technology. The combination group was treated with photon rejuvenation technology combined with tacrolimus ointment and Compound Cortex Phellodendri Liquid. The course of treatment was 8 weeks. Skin barrier function indices [transepidermal water loss (TEWL), the moisture and oil contents of skin], the therapeutic effect after treatment and the scores of dermatology life quality index (DLQI) before and after treatment were compared among the 3 groups. The therapeutic effects after treatment of the 3 groups were compared. The adverse reactions during treatment and relapse situation after treatment with a 8-week follow-up were recorded and compared. Results There were significant differences in the values of skin barrier function indices, the scores of DLQI and the therapeutic effect after treatment among the 3 groups (P < 0.05). After treatment, TEWL score of the combination group was lower than the photon group and Cortex Phellodendri group, while the photon group was lower than the Cortex Phellodendri group (P < 0.05). Moisture and oil contents of skin, the therapeutic effect distribution after treatment of the combination group were higher than the photon group and Cortex Phellodendri group, while the photon group was higher than the Cortex Phellodendri group, while the scores of DLQI of the combination group were lower than the photon group and Cortex Phellodendri group, which of photon group were lower than those of Cortex Phellodendri group (P < 0.05). There were no statistically significant differences of adverse reactions among three groups (P > 0.05). There was no recurrence situation in a 8-week follow-up after treatment among three groups. Conclusion The photon rejuvenation technology combined with Tacrolimus Ointment and Compound Cortex Phellodendri Liquid in the treatment of FCAD has obvious effect, which can significantly improve the skin barrier function and the quality of life. The treatment is safe and worth of clinical promotion.

[Key words] Photon rejuvenation technology; Compound Cortex Phellodendri Liquid; Facial corticosteroid addictive dermatitis

近年来,随着激素类药膏或含皮质激素类化妆品的不规范使用,面部激素依赖性皮炎(facial corticosteroid addictive dermatitis,FCAD)的发病率逐年升高,受到医疗工作者的广泛关注[1]。FCAD以激素依赖及反复发作为主要特征,由于长期依赖性应用激素,导致皮肤屏障功能受损严重,临床中多以对症治疗,但急症期消退后,皮肤抵抗力仍然较弱,导致病情反复,难以治愈,给患者身心健康带来严重伤害[2]。……

登录APP查看全文